Aim <p>This study aimed to evaluate the histological response of mandibular mature premolars with symptomatic irreversible pulpitis (SIP) following cervical pulpotomy using three bioactive materials: Mineral Trioxide Aggregate (MTA), Biodentine, and TotalFill BC RRM.</p> Materials and methods <p>40 young, healthy patients with 60 mandibular mature premolars with deep carious lesions, diagnosed with SIP and scheduled for orthodontic extraction, were included. Premolars were randomly assigned to three groups based on the bioactive material used during pulpotomy (MTA, Biodentine, or TotalFill BC RRM). Each group was divided into two subgroups according to the follow-up period: the first subgroup was extracted after 1 week, and the second after 6 months. Histological evaluations assessed pulpal inflammation, the degree of pulp disorganization, and dentinal-like bridge formation. Kruskal-Wallis and Wilcoxon tests were used to analyse the data. The significance level was set at α = 0.05.</p> Results <p>No significant differences were observed among the bioactive materials in histological evaluations at the two time points (<i>p</i> &gt; 0.005). Most samples exhibited an inflammatory response and marked histological disruption during the first week. Over the six-month follow-up period, inflammation and histological disruption decreased progressively compared with the one-week follow-up (<i>p</i> &lt; 0.05). Moreover, a noticeable dentinal-like bridge was observed in most samples after six months, compared with the one-week follow-up (<i>p</i> &lt; 0.001).</p> Conclusion <p>The histological response following cervical pulpotomy with bioactive materials (MTA, Biodentine, and TotalFill BC RRM) in permanent mature teeth with SIP is comparable, indicating their similar effectiveness.</p> Trial registration <p>The trial protocol was registered retrospectively at the Registry of ISRCTN (Trial ID: ISRCTN16268487) on 17/03/2025.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Histological evaluation of vital full pulpotomy techniques in permanent mature teeth with symptomatic irreversible pulpitis using three calcium silicate cements: a randomized controlled trial

  • Sarah Nassri,
  • Abdulghani Mardini,
  • Osama Aljabban,
  • Yasser Alsayed Tolibah

摘要

Aim

This study aimed to evaluate the histological response of mandibular mature premolars with symptomatic irreversible pulpitis (SIP) following cervical pulpotomy using three bioactive materials: Mineral Trioxide Aggregate (MTA), Biodentine, and TotalFill BC RRM.

Materials and methods

40 young, healthy patients with 60 mandibular mature premolars with deep carious lesions, diagnosed with SIP and scheduled for orthodontic extraction, were included. Premolars were randomly assigned to three groups based on the bioactive material used during pulpotomy (MTA, Biodentine, or TotalFill BC RRM). Each group was divided into two subgroups according to the follow-up period: the first subgroup was extracted after 1 week, and the second after 6 months. Histological evaluations assessed pulpal inflammation, the degree of pulp disorganization, and dentinal-like bridge formation. Kruskal-Wallis and Wilcoxon tests were used to analyse the data. The significance level was set at α = 0.05.

Results

No significant differences were observed among the bioactive materials in histological evaluations at the two time points (p > 0.005). Most samples exhibited an inflammatory response and marked histological disruption during the first week. Over the six-month follow-up period, inflammation and histological disruption decreased progressively compared with the one-week follow-up (p < 0.05). Moreover, a noticeable dentinal-like bridge was observed in most samples after six months, compared with the one-week follow-up (p < 0.001).

Conclusion

The histological response following cervical pulpotomy with bioactive materials (MTA, Biodentine, and TotalFill BC RRM) in permanent mature teeth with SIP is comparable, indicating their similar effectiveness.

Trial registration

The trial protocol was registered retrospectively at the Registry of ISRCTN (Trial ID: ISRCTN16268487) on 17/03/2025.